CareDx, Inc.
Close on Oct 19, 2026
- Market cap
- $3.58B
- P/E (TTM)
- 32.4
- Dividend yield
- –
About CareDx
Services-Medical Laboratories, SIC 8071
CareDx, Inc. is a precision medicine company specializing in solutions for transplant patients and organ health management. Operating as a single reportable segment, the organization provides non-invasive molecular testing, laboratory products, digital health applications, and specialized pharmacy services across the pre- and post-transplant continuum. Its commercial testing portfolio includes gene expression profiling and donor-derived cell-free DNA tests for kidney, heart, and lung transplant surveillance. Additionally, the company offers human leukocyte antigen typing products, diagnostic next-generation sequencing kits, and clinical workflow software. CareDx serves clinicians, transplant centers, dialysis centers, healthcare providers, and biopharmaceutical partners.
The company operates primarily across the United States and Europe, with its main assets and operations situated in the United States and Sweden. Its digital health software is utilized in more than 170 transplant facilities throughout the United States. CareDx maintains primary operations in Brisbane, California; Omaha, Nebraska; and Stockholm, Sweden, with its corporate headquarters located in Brisbane, California.
Summary of the business section of CareDx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CareDx, Inc.
- Founded
- 1998
- Headquarters
- Brisbane, CA
- Address
- 8000 Marina Blvd, 4th Floor 94005
- Phone
- (415) 287-2300
- Website
- www.caredx.com
- Employees
- 765, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- CDNA
- Exchange
- Nasdaq
- Shares outstanding
- 52M, Jul 27, 2026
- Public float
- $1.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1217234
- CUSIP
- 14167L103
- ISIN
- US14167L1035
- LEI
- 549300NQOFKL9NON0U06
- EIN
- 94-3316839
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Walter Hanna JR | President and CEO, Director | 721,448 |
| Keith Kennedy | CFO & COO | 211,704 |
| Jessica Meng | Chief Commercial Officer | 161,599 |
| Jeffrey Adam Novack | Secretary and General Counsel | 106,075 |
| Nathan Smith | Chief Financial Officer | 75,000 |
| Abhishek Jain | Chief Financial Officer | 319,725 |
| Christine Cournoyer | Director | 42,943 |
| Michael Goldberg | Director | 152,783 |
| George Bickerstaff | Director | 134,061 |
| Hannah Valantine | Director | 36,786 |
| Fred E. Cohen | Director | 165,060 |
| Richard Bryan Riggsbee | Director | 39,312 |
| Suresh Gunasekaran | Director | 37,248 |
| Arthur A. Torres | Director | 38,665 |
| Peter Maag | Director | 309,846 |
| William A. Hagstrom | Director | 73,370 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.John W.Hanna | $7.18M | $3.45M | $2.13M | $26 | $125 |
| FY2025 Mr.Johnson | $0 | $0 | $2.13M | $26 | $125 |
| FY2024 Dr Seeto | $0 | $0 | $2.99M | $30 | $93 |
| FY2024 Mr.John W.Hanna | $9.42M | $24.18M | $2.99M | $30 | $93 |
| FY2024 Mr.Johnson | $2.94M | $7.44M | $2.99M | $30 | $93 |
| FY2023 Dr Seeto | $10.55M | $6.67M | $4.62M | $17 | $94 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“On December 31, 2025, we had 765 employees, of which 761 were full-time employees.”
Corporate history
Events identified from SEC filings